Tina Marriott - Feb 9, 2024 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: President and COO
Signature: /s/ Jonathan Golightly, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Feb 9, 2024
Transactions value $: -$28,252
Form type: 4
Date filed: 2/13/2024, 07:00 PM
Previous filing: Jan 29, 2024
Next filing: Feb 16, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Award	$0	+9.66K	+2.33%	$0.00	424K	Feb 9, 2024	Direct	F1
transaction	RXRX	Class A Common Stock	Award	$0	+224K	+52.8%	$0.00	648K	Feb 9, 2024	Direct	F2
transaction	RXRX	Class A Common Stock	Tax liability	-$28.3K	-2.8K	-0.43%	$10.09	645K	Feb 9, 2024	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	RXRX	Stock Option (Right to Buy)	Award	$0	+448K		$0.00	448K	Feb 9, 2024	Class A Common Stock	448K	$10.09	Direct	F8
holding	RXRX	Stock Option (Right to Buy)						434K	Feb 9, 2024	Class A Common Stock	0	$8.55	Direct	F4
holding	RXRX	Stock Option (Right to Buy)						504K	Feb 9, 2024	Class A Common Stock	0	$1.06	Direct	F5
holding	RXRX	Stock Option (Right to Buy)						159K	Feb 9, 2024	Class A Common Stock	0	$11.40	Direct	F6
holding	RXRX	Stock Option (Right to Buy)						4.78K	Feb 9, 2024	Class A Common Stock	0	$11.40	Direct
holding	RXRX	Stock Option (Right to Buy)						150K	Feb 9, 2024	Class A Common Stock	0	$2.48	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This RSU vested immediately upon the grant date.
F2	This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2024 and every three months thereafter.
F3	Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units.
F4	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F5	Twenty-Five percent (25%) of the shares subject to the award (the stock option grant was for a total of 765,000 shares prior to exercise) shall vest one year after July 16, 2018, or the Annual Vesting Commencement Date, and one-forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Annual Vesting Commencement Date.
F6	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7	One forty-eighth (1/48th) of the shares subject to the award shall vest one month after December 31, 2020, or the Monthly Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Monthly Vesting Commencement Date.
F8	The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2024, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.